Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation
Open Access
- 20 March 2001
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 98 (7) , 4202-4208
- https://doi.org/10.1073/pnas.071054698
Abstract
The objective of this study was to elucidate the mechanisms by which nitric oxide (NO) inhibits rat aortic smooth muscle cell (RASMC) proliferation. Two products of the arginine-NO pathway interfere with cell growth by distinct mechanisms. NG-hydroxyarginine and NO appear to interfere with cell proliferation by inhibiting arginase and ornithine decarboxylase (ODC), respectively. S-nitroso-N-acetylpenicillamine, (Z)-1-[N-(2-aminoethyl)-N-(2-aminoethyl)-amino]-diazen-1-ium-1,2-diolate, and a nitroaspirin derivative (NCX 4016), each of which is a NO donor agent, inhibited RASMC growth at concentrations of 1–3 μM by cGMP-independent mechanisms. The cytostatic action of the NO donor agents as well as α-difluoromethylornithine (DFMO), a known ODC inhibitor, was prevented by addition of putrescine but not ornithine. These observations suggested that NO, like DFMO, may directly inhibit ODC. Experiments with purified, recombinant mammalian ODC revealed that NO inhibits ODC possibly by S-nitrosylation of the active site cysteine in ODC. DFMO, as well as the NO donor agents, interfered with cellular polyamine (putrescine, spermidine, spermine) production. Conversely, increasing the expression and catalytic activity of arginase I in RASMC either by transfection of cells with the arginase I gene or by induction of arginase I mRNA with IL-4 resulted in increased urea and polyamine production as well as cell proliferation. Finally, coculture of rat aortic endothelial cells, which had been pretreated with lipopolysaccharide plus a cytokine mixture to induce NO synthase and promote NO production, caused NO-dependent inhibition of target RASMC proliferation. This study confirms the inhibitory role of the arginine-NO pathway in vascular smooth muscle proliferation and indicates that one mechanism of action of NO is cGMP-independent and attributed to its capacity to inhibit ODC.Keywords
This publication has 32 references indexed in Scilit:
- Nitric Oxide Inhibits Ornithine Decarboxylase by S-NitrosylationBiochemical and Biophysical Research Communications, 1999
- Sodium nitroprusside inhibits proliferation and putrescine synthesis in human colon carcinoma cellsFEBS Letters, 1996
- Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative.Journal of Clinical Investigation, 1995
- Involvement of nitric oxide in IFN-γ-mediated reduction of microvessel smooth muscle cell proliferationMolecular Immunology, 1995
- Ornithine decarboxylase as a target for chemopreventionJournal of Cellular Biochemistry, 1995
- Inhibition of Rat Liver Arginase by an Intermediate in NO Biosynthesis, NG-Hydroxy-L-arginine: Implications for the Regulation of Nitric Oxide Biosynthesis by ArginaseBiochemical and Biophysical Research Communications, 1994
- Ornithine decarboxylase as an enzyme target for therapyPharmacology & Therapeutics, 1992
- Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginineThe Lancet, 1991
- Inhibition by nitric oxide and nitric oxide-producing vasodilators of DNA synthesis in vascular smooth muscle cellsEuropean Journal of Pharmacology: Molecular Pharmacology, 1990
- Nitric oxide-generating vasodilators inhibit mitogenesis and proliferation of BALBc 3T3 fibroblasts by a cyclic GMP-independent mechanismBiochemical and Biophysical Research Communications, 1990